Drusilla L Burns

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Biochemistry of type IV secretion
    D L Burns
    CBER, US Food and Drug Administration HFM 434, Building 29 Room 418 8800 Rockville Pike Bethesda MD 20892 USA
    Curr Opin Microbiol 2:25-9. 1999
  2. pmc Analysis of subassemblies of pertussis toxin subunits in vivo and their interaction with the ptl transport apparatus
    Drusilla L Burns
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland, USA
    Infect Immun 72:5365-72. 2004
  3. ncbi request reprint Type IV transporters of pathogenic bacteria
    Drusilla L Burns
    United States Food and Drug Administration HFM 434 Building 29, Room 130, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Curr Opin Microbiol 6:29-34. 2003
  4. pmc Requirements for assembly of PtlH with the pertussis toxin transporter apparatus of Bordetella pertussis
    Anita Verma
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 75:2297-306. 2007
  5. pmc Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays
    Rebecca A Brady
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 17:1390-7. 2010
  6. pmc Comparison of three anthrax toxin neutralization assays
    Miriam M Ngundi
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 17:895-903. 2010
  7. pmc Stabilization of the pertussis toxin secretion apparatus by the C terminus of PtlD
    Anita Verma
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, CBER, FDA HFM 434, Building 29, Room 130, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Bacteriol 190:7285-90. 2008
  8. pmc Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen
    Anita Verma
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Infect Immun 81:278-84. 2013
  9. pmc Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action
    Miriam M Ngundi
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:731-9. 2012
  10. pmc Analysis of relative levels of production of pertussis toxin subunits and Ptl proteins in Bordetella pertussis
    Anissa M Cheung
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 72:2057-66. 2004

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Biochemistry of type IV secretion
    D L Burns
    CBER, US Food and Drug Administration HFM 434, Building 29 Room 418 8800 Rockville Pike Bethesda MD 20892 USA
    Curr Opin Microbiol 2:25-9. 1999
    ....
  2. pmc Analysis of subassemblies of pertussis toxin subunits in vivo and their interaction with the ptl transport apparatus
    Drusilla L Burns
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland, USA
    Infect Immun 72:5365-72. 2004
    ..These results indicate that subassemblies of the toxin consisting of the S1 subunit and a partial B oligomer can interact with the Ptl system...
  3. ncbi request reprint Type IV transporters of pathogenic bacteria
    Drusilla L Burns
    United States Food and Drug Administration HFM 434 Building 29, Room 130, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Curr Opin Microbiol 6:29-34. 2003
    ..Recent findings have shed light on the architecture of type IV transporters and the roles that these transporters play in pathogenesis...
  4. pmc Requirements for assembly of PtlH with the pertussis toxin transporter apparatus of Bordetella pertussis
    Anita Verma
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 75:2297-306. 2007
    ..Based on these data, a model for the assembly of the Ptl transporter-PT complex is presented...
  5. pmc Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays
    Rebecca A Brady
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 17:1390-7. 2010
    ..These findings provide information that will be useful when linking animal protection data to humans via an antibody bridge to establish efficacy of new anthrax vaccines...
  6. pmc Comparison of three anthrax toxin neutralization assays
    Miriam M Ngundi
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 17:895-903. 2010
    ..5-fold. However, because toxin neutralization assays will likely be used to establish the efficacies of new anthrax vaccines, our findings should be considered when assay outputs are interpreted...
  7. pmc Stabilization of the pertussis toxin secretion apparatus by the C terminus of PtlD
    Anita Verma
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, CBER, FDA HFM 434, Building 29, Room 130, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Bacteriol 190:7285-90. 2008
    ..Further analysis demonstrated that a stretch of 10 amino acids at the C-terminal end of PtlD (amino acids 425 to 434) contributes to transporter stability...
  8. pmc Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen
    Anita Verma
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Infect Immun 81:278-84. 2013
    ....
  9. pmc Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action
    Miriam M Ngundi
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:731-9. 2012
    ..These results may aid in optimal design of new vaccines and antibody therapies against anthrax...
  10. pmc Analysis of relative levels of production of pertussis toxin subunits and Ptl proteins in Bordetella pertussis
    Anissa M Cheung
    Laboratory of Respiratory and Special Pathogens, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 72:2057-66. 2004
    ..These results represent an important first step in assessing the stoichiometric relationship of pertussis toxin and its transporter within the bacterial cell...
  11. pmc Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant
    Leslie Wagner
    Center for Biologics Evaluation and Research, Food and Drug Administration Bethesda, MD, USA
    Clin Vaccine Immunol 19:1465-73. 2012
    ..These results demonstrate that storage of rPA-Alhydrogel formulations can lead to structural alteration of the protein and loss of the ability to elicit toxin-neutralizing antibodies...
  12. pmc Membrane localization of the S1 subunit of pertussis toxin in Bordetella pertussis and implications for pertussis toxin secretion
    Karen M Farizo
    Laboratory of Respiratory and Special Pathogens, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 70:1193-201. 2002
    ..pertussis. Thus, outer membrane-bound S1 may serve as a nucleation site for assembly with the B oligomer and for interactions with the Ptl transport system...
  13. pmc Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays
    Anita Verma
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 16:1405-12. 2009
    ..These findings should be considered when interpreting anthrax toxin neutralization assay output...
  14. pmc Importance of holotoxin assembly in Ptl-mediated secretion of pertussis toxin from Bordetella pertussis
    K M Farizo
    Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 68:4049-54. 2000
    ..Conversely, the S1 subunit is also not secreted by a Ptl-mediated mechanism in the absence of the B oligomer. Thus, an assembled holotoxin is required for Ptl-mediated export of pertussis toxin from B. pertussis...
  15. pmc Essential role of the consensus nucleotide-binding site of PtlH in secretion of pertussis toxin from Bordetella pertussis
    S I Kotob
    Laboratory of Pertussis, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Bacteriol 179:7577-80. 1997
    ..Moreover, the observed dominant negative phenotype suggests that PtlH either functions as a multimer or interacts with another component necessary for secretion of PT...
  16. pmc Identification and characterization of PtlC, an essential component of the pertussis toxin secretion system
    D M Cook
    Laboratory of Pertussis, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 67:754-9. 1999
    ..Moreover, the observed dominant negative phenotype suggests that PtlC either functions as a multimer or interacts with some other component(s) necessary for secretion of PT...
  17. ncbi request reprint Evidence for a ninth gene, ptlI, in the locus encoding the pertussis toxin secretion system of Bordetella pertussis and formation of a PtlI-PtlF complex
    K M Farizo
    Division of Bacterial Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Biol Chem 271:31643-9. 1996
    ..In B. pertussis, PtlI and PtlF co-precipitated with antibody to PtlF. These findings demonstrate the existence of PtlI and a PtlI-PtlF complex, providing the first description of an interaction between Ptl proteins...
  18. pmc Detection and subcellular localization of three Ptl proteins involved in the secretion of pertussis toxin from Bordetella pertussis
    F D Johnson
    Division of Bacterial Products, Food and Drug Administration, Bethesda, Maryland 20892
    J Bacteriol 176:5350-6. 1994
    ..pertussis into other Bordetella spp. results in production of the toxin but not secretion of the toxin...
  19. pmc Immunogenicity Analysis of Staphylococcus aureus Clumping Factor A Genetic Variants
    Rebecca A Brady
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Clin Vaccine Immunol 20:1338-40. 2013
    ..This work indicates that immune responses elicited by ClfA may, at least in part, be dependent on the strain of origin of the ClfA. ..
  20. pmc Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay
    Anita Verma
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 15:1737-41. 2008
    ..These results demonstrate that care must be taken to ensure that LF preparations used in standardized cell-based assays are not altered at their N-terminal ends...
  21. pmc Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis
    S Z Hausman
    Division of Bacterial Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 64:4020-6. 1996
    ..These results indicate that despite a number of amino acid changes in the sequences of the toxins, the toxins encoded by B. bronchiseptica and B. parapertussis are active...
  22. pmc Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection
    Rebecca A Brady
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e63040. 2013
    ..aureus disease without conferring protection against other disease presentations and thus underscore a significant challenge in S. aureus vaccine development...
  23. pmc Importance of srtA and srtB for growth of Bacillus anthracis in macrophages
    Steven D Zink
    CBER, FDA HFM 434, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Infect Immun 73:5222-8. 2005
    ..anthracis may be critical in the early stages of inhalation anthrax...